Healx

Healx is a United Kingdom-based technology company founded in 2014 that is transforming the field of drug discovery using AI-driven methodologies. The company's mission focuses on developing treatments for rare diseases, an area with tremendous unmet needs, as only 5% of the over 10,000 known rare diseases currently have approved treatments. Healx's approach combines cutting-edge AI technology with robust drug discovery and development expertise.

As of its last funding round on 01 July 2025, Healx secured a Growth Equity VC investment led by SCI Ventures. This injection of capital aims to scale its research and development efforts further and address the needs of the 400 million people globally affected by rare diseases.

Positioned at the intersection of several high-growth industries, including Biopharma, Biotechnology, and Life Sciences, Healx is strategically placed to deliver significant patient impact while providing value to its investors.